The biopharmaceutical company Inventiva has disclosed the procedures for accessing the preparatory documents for the mixed general meeting to be held on November 27, 2025, in Paris. According to the press release, shareholders can access these documents on the company's website and at its headquarters starting from the fifteenth day before the meeting date. The agenda and draft resolutions are published in the Official Legal Announcements Bulletin (BALO).
Key Topics of the General Meeting
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The general meeting will focus on the approval of the remuneration policy for the new CEO, Andrew Obenshain, and the terms of departure for his predecessor, Frédéric Cren.
Ongoing Clinical Trials
Inventiva continues its Phase 3 clinical trials for Lanifibranor, aimed at treating NASH, a chronic liver disease. The company, listed on Euronext Paris and NASDAQ, emphasizes that its clinical results are subject to regulatory approval. Additional information about ongoing clinical trials is available in the company's regulatory filings.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 0€
Risks mentioned
Aucune garantie que les bons de souscription seront exercés en totalité.
Inventiva a un historique d'exploitation limité et a subi des pertes importantes.
Opportunities identified
Estime que sa trésorerie lui permettra de financer ses activités jusqu'à la mi-premier trimestre 2027.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
